Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ettrabopa for prophylactic treatment of chemotherapy-induced thrombocytopenia
ChiCTR2000041351Phase 3Recruiting
- Sponsor
- Hangzhou First People's Hospital
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of eltrombopag in chemotherapy-induced thrombocytopenia (CIT) (2 arms), sponsored by Hangzhou First People's Hospital. Primary endpoint: Lowest platelet count after chemotherapy. Started Feb 2021; status: recruiting.
02
Drugs
eltrombopag
03
Conditions
chemotherapy-induced thrombocytopenia (CIT)
Beyond the preview
Go deeper on ChiCTR2000041351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000041351.